Colon cancer progression is driven by APEX1-mediated upregulation of Jagged

Authors:
  • MKMi-Hwa Kim
    Mi-Hwa Kim
  • HKHong-Beum Kim
    Hong-Beum Kim
  • SYSang Pil Yoon
    Sang Pil Yoon
  • SLSung-Chul Lim
    Sung-Chul Lim
  • MCMan Jin Cha
    Man Jin Cha
  • YJYoung Jin Jeon
    Young Jin Jeon
  • SPSang Gon Park
    Sang Gon Park
  • ICIn-Youb Chang
    In-Youb Chang

Abstract
Aberrant expression of apurinic-apyrimidinic endonuclease–1 (APEX1) has been reported in numerous human solid tumors and is positively correlated with cancer progression; however, the role of APEX1 in tumor progression is poorly defined. Here, we show that APEX1 contributes to aggressive colon cancer behavior and functions as an upstream activator in the Jagged1/Notch signaling pathway. APEX1 overexpression or knockdown in human colon cancer cell lines induced profound changes in malignant properties such as cell proliferation, anchorage-independent growth, migration, invasion, and angiogenesis in vitro and in tumor formation and metastasis in mouse xenograft models. These oncogenic effects of APEX1 were mediated by the upregulation of Jagged1, a major Notch ligand. Furthermore, APEX1 expression was associated with Jagged1 in various colon cancer cell lines and in tissues from colon cancer patients. This finding identifies APEX1 as a positive regulator of Jagged1/Notch activity and suggests that it is a potential therapeutic target in colon cancers that exhibit high levels of Jagged1/Notch signaling.

This publication has 47 references indexed in Scilit: